Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
May 11, 2018•10 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West considers whether the results from the CheckMate 227 trial comparing nivolumab/ipilimumab to chemotherapy in patients with advanced NSCLC & high tumor mutation burden should change our management: AreTMB & nivo/ipi ready for prime time?
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast